DHDale Han

Dale Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dale Han has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • WITHDRAWN

    by Sarayu Subramanian, Dale Han

  • The Efficacy and Evolution of Surgical Management Based on Cancer Biology

    by Richard J. Straker, Hayley Standage, Giorgos C. Karakousis, Dale Han

  • ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?

    by S. Morrison, Gang Han, Faith Elenwa, John T. Vetto, Graham Fowler, Stanley P. L. Leong, Mohammed Kashani‐Sabet, Barbara A. Pockaj, Heidi E. Kosiorek, Jonathan S. Zager, et al.

  • Regression is significantly associated with outcomes for patients with melanoma

    by Sarayu Subramanian, Gang Han, Natalie Olson, Stanley P. Leong, Mohammed Kashani-Sabet, Richard L. White, Jonathan S. Zager, Vernon K. Sondak, Jane L. Messina, Barbara Pockaj, et al.


  • Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence‐free survival

    by Sarayu Subramanian, Gang Han, Natalie Olson, Stanley P. Leong, Mohammed Kashani‐Sabet, Richard L. White, Jonathan S. Zager, Vernon K. Sondak, Jane L. Messina, Barbara Pockaj, et al.

    Background and Objectives: The prognostic significance of regression in predicting melanoma recurrences is unknown. We present a large multicenter study correlating regression with recurrence.Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with regression data. Clinicopathologic factors were correlated with overall and first‐site of recurrence and with recurrence‐free survival (RFS).Results: There were 4790 patients and the median follow‐up was 39.6 months. Regression and recurrences were seen in 1081 (22.6%) and 773 (16.1%) cases, respectively. First‐site locoregional and distant recurrences were seen in 412 (8.6%) and 352 (7.3%) patients, respectively. Regression was seen in 15.8% and 24.7% of all cases with and without recurrences (p < 0.0001), respectively, while regression was seen in 14.3% and 17.9% of first‐site locoregional and distant recurrent cases, respectively, compared with 23.3% and 22.9% of patients with regression and without first‐site locoregional and distant recurrences, respectively (p = 0.29). On multivariable analysis, after controlling for age, gender, thickness, ulceration, lymphovascular invasion, and sentinel lymph node status, regression significantly predicted improved RFS (p = 0.004) and fewer first‐site regional recurrences (p = 0.017).Conclusion: Our data suggest that regression is a favorable prognostic marker in melanoma and predicts significantly better RFS and decreased first‐site regional recurrences.


  • Current management of melanoma patients with nodal metastases

    by Dale Han, Alexander C. J. van Akkooi, Richard J. Straker, Adrienne B. Shannon, Giorgos C. Karakousis, Lin Wang, Kevin B. Kim, Douglas Reintgen

    The management of melanoma patients with nodal metastases has undergone dramatic changes over the last decade. In the past, the standard of care for patients with a positive sentinel lymph node biopsy (SLNB) was a completion lymph node dissection (CLND), while patients with palpable macroscopic nodal disease underwent a therapeutic lymphadenectomy in cases with no evidence of systemic spread. However, studies have shown that SLN metastases present as a spectrum of disease, with certain SLN-based factors being prognostic of and correlated with outcomes. Furthermore, the results of key clinical trials demonstrate that CLND provides no survival benefit over nodal observation in positive SLN patients, while other clinical trials have shown that adjuvant immune checkpoint inhibitor therapy or targeted therapy after CLND is associated with a recurrence-free survival benefit. Given the efficacy of these systemic therapies in the adjuvant setting, these agents are now being evaluated and utilized as neoadjuvant treatments in patients with regionally-localized or resectable metastatic melanoma. Multiple options now exist to treat melanoma patients with nodal disease, and determining the best treatment course for a particular case requires an in-depth knowledge of current data and an informed discussion with the patient. This review will provide an overview of the various options for treating melanoma patients with nodal metastases and will discuss the data that supported the development of these treatment options.


  • What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?

    by Hayley Standage, Alyssa R. Hersh, Aaron Caughey, Matthew Taylor, John Vetto, Dale Han

    Background Survival for positive sentinel lymph node (SLN) patients does not differ between completion lymph node dissection (CLND) and nodal observation (OBS). However, treating these patients with CLND and checkpoint inhibitors, such as pembrolizumab (PEM), improves outcomes. This study evaluated the cost-effectiveness of OBS, CLND, and CLND with PEM (CLND-PEM) treatments. Methods A Markov model was designed to simulate treatment for a theoretical cohort of 1000 positive SLN patients per therapy with a 5-year follow-up period. An intervention was cost-effective if its incremental cost-effectiveness ratio among therapies was below the willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY). Results Compared with CLND or CLND-PEM, OBS resulted in fewer lymphedema cases but in more disease recurrences. Compared with OBS, CLND had higher costs and lower QALYs. Although CLND-PEM had a lower number of recurrences and deaths than OBS or CLND, it had higher costs and lower QALYs than OBS, and thus was not cost-effective. However, with the effects of CLND from CLND-PEM removed, allowing evaluation of PEM effects alone (PEM alone), the resulting QALYs were the highest, but PEM alone still was not cost-effective compared with OBS ($1.2 million per QALY). By reducing the drug cost to less than $14,404 per patient, PEM alone would become cost-effective. Conclusions Compared with CLND, CLND-PEM, and PEM alone, OBS was cost-effective for managing positive SLN patients. Although CLND-PEM and PEM alone result in fewer recurrences and deaths, these therapies were not cost-effective due to the quality-of-life decrement of CLND and the current high drug cost of PEM.


  • Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma

    by Steven Morrison, Dale Han

    Opinion statement The vast majority of patients newly diagnosed with melanoma present with clinically localized disease, and sentinel lymph node biopsy (SLNB) is a standard of care in the management of these patients, particularly in intermediate thickness cases, in order to provide important prognostic data. However, SLNB also has an important role in the management of patients with other subtypes of melanoma such as thick melanomas, certain thin melanomas, and specific histologic variants of melanoma such as desmoplastic melanoma. Furthermore, there have been technical advances in the SLNB technique, such as the development of newer radiotracers and use of SPECT/CT, and there is some data to suggest performing a SLNB may be therapeutic. Finally, the management of patients with a positive sentinel lymph node (SLN) has undergone dramatic changes over the past several years based on the results of recent important clinical trials. Treatment options for patients with SLN metastases now include surveillance, completion lymph node dissection, and adjuvant therapy with checkpoint inhibitors and targeted therapy. SLNB continues to play a crucial role in the management of patients with melanoma, allowing for risk stratification, potential regional disease control, and further treatment options for patients with a positive SLN.


  • Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?

    by Dale Han, Gang Han, Steven Morrison, Stanley P. Leong, Mohammed Kashani-Sabet, John Vetto, Richard White, Schlomo Schneebaum, Barbara Pockaj, Nicola Mozzillo, et al.